Down 99%, biotech firm 180 Life Sciences pivots to crypto with ETH bet
The Nasdaq-listed biotechnology firm is raising $425 million for its ETH strategy, joining a parade of penny stocks investing in cryptocurrencies as their business flounders.
Archive context
Older archive item. Useful for background and entity history, but not a fresh market-moving signal.
The Nasdaq-listed biotechnology firm is raising $425 million for its ETH strategy, joining a parade of penny stocks investing in cryptocurrencies as their business flounders.
Why this matters
This ethereum story adds another data point to the current market tape and is useful when read alongside nearby source coverage.
Original source
Read on CointelegraphRelated market context
Bain Capital Leads $37.5M Investment in Bitcoin Life Insurance Firm
Bitcoin-denominated life insurer Meanwhile raised $37.5 million in new funding led by Bain Capital Crypto, bringing its total capi...
Evernorth XRP Treasury Merger Brings 473 Million XRP to Nasdaq as XRPN Debuts October 12
The transaction gives public-market investors another route to gain exposure to XRP through a company that actively manages its di...
This Sam Altman-Backed Life Insurer Runs Entirely on Bitcoin, and Just Raised $37.5 Million
The Bermuda-based insurer, which runs entirely on Bitcoin, drew the funding from existing backers led by Bain Capital Crypto after...
Bitcoin’s weekend rebound faces an $80,400 test after nearly $730 million in ETF outflows
Bitcoin traded near $82,900 in PerpFinder’s Oct. 10, 09:36 UTC snapshot, with traders watching whether the weekend rebound brings...
More Orange: Saylor Hints at Growing Strategy’s 848K Bitcoin Stash
Strategy could expand its bitcoin holdings after Michael Saylor posted another orange-themed buying hint. His latest message follo...
Bitcoin companies are learning that holding forever takes cash
Metaplanet sold 10,000 BTC and bought back 11,000 at a higher average price to show it was willing to sell its Bitcoin. The Japane...